HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes


Shaina Bruce, Sharon Wu, Alex Farrell, Matthew Oberley, Ira Winer, Britt Erickson, Nathaniel Jones, Premal Thaker, Matthew Powell

Key Finding:

5% of endometrioid endometrial adenocarcinomas are HER2+, as assessed by ERBB2 expression, and have a hot immune phenotype. 

Download Publication